Joseph Catanzaro
Stock Analyst at Mizuho
(3.95)
# 582
Out of 5,147 analysts
104
Total ratings
47.06%
Success rate
13.08%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Initiates: Outperform | $19 | $11.14 | +70.56% | 2 | Feb 23, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $15.97 | +119.16% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $9.80 | -28.57% | 6 | Jan 20, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $6.5 → $10 | $5.37 | +86.22% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $102.02 | +40.17% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $17.50 | +122.86% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $7.68 | +564.06% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $16.78 | +7.27% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $43.02 | +23.20% | 1 | Dec 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $81 → $120 | $91.35 | +31.36% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $30.11 | +59.42% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $105 | $70.12 | +49.74% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.86 | +55.44% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.06 | +273.29% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $148.95 | -26.15% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $44.06 | -13.75% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $14.19 | +5.71% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $69.53 | -23.77% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.94 | +415.46% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.37 | +1,286.86% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $10.34 | +83.75% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.47 | +507.29% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $13.49 | +166.86% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $10.60 | +277.36% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.94 | +67.79% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.25 | +100.00% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.52 | +1,873.68% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.17 | +1,616.74% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.53 | -30.83% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.08 | -13.34% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.54 | -40.94% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $30.50 | +555.74% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $15.45 | +126.54% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.51 | +3,886.71% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.27 | +692.95% | 3 | Apr 7, 2020 |
Tango Therapeutics
Feb 23, 2026
Initiates: Outperform
Price Target: $19
Current: $11.14
Upside: +70.56%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $15.97
Upside: +119.16%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $9.80
Upside: -28.57%
CytomX Therapeutics
Jan 20, 2026
Maintains: Overweight
Price Target: $6.5 → $10
Current: $5.37
Upside: +86.22%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $102.02
Upside: +40.17%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $17.50
Upside: +122.86%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $7.68
Upside: +564.06%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $16.78
Upside: +7.27%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $43.02
Upside: +23.20%
Kymera Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $91.35
Upside: +31.36%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $30.11
Upside: +59.42%
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $70.12
Upside: +49.74%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.86
Upside: +55.44%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.06
Upside: +273.29%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $148.95
Upside: -26.15%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $44.06
Upside: -13.75%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $14.19
Upside: +5.71%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $69.53
Upside: -23.77%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.94
Upside: +415.46%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.37
Upside: +1,286.86%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $10.34
Upside: +83.75%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.47
Upside: +507.29%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $13.49
Upside: +166.86%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $10.60
Upside: +277.36%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.94
Upside: +67.79%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.25
Upside: +100.00%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.52
Upside: +1,873.68%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.17
Upside: +1,616.74%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.53
Upside: -30.83%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.08
Upside: -13.34%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.54
Upside: -40.94%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $30.50
Upside: +555.74%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $15.45
Upside: +126.54%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.51
Upside: +3,886.71%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.27
Upside: +692.95%